Related references
Note: Only part of the references are listed.Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
Piyada Sitthideatphaiboon et al.
SCIENTIFIC REPORTS (2022)
Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US
Fatemeh Asad Zadeh Vosta Kolaei et al.
FRONTIERS IN ONCOLOGY (2022)
Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer
Xiaoyan Si et al.
THORACIC CANCER (2021)
P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
E. Felip et al.
Journal of Thoracic Oncology (2021)
OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
A. Spira et al.
Journal of Thoracic Oncology (2021)
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer
Jessica J. Lin et al.
CLINICAL CANCER RESEARCH (2021)
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer
Edward B. Garon et al.
DRUGS (2021)
Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations
Yasuhiro Kato et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)
Crizotinib in Patients With MET-Amplified NSCLC
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
Lun-Xi Peng et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
N. B. Leighl et al.
ANNALS OF ONCOLOGY (2021)
METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society
Yasushi Yatabe et al.
Japanese Journal of Lung Cancer (2021)
METex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with METex14 skipping NSCLC treated with tepotinib.
Paul K. Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
Xiuning Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant advanced non-small cell lung cancer (NSCLC).
Liu Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.
Jyoti D. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
Shun Lu et al.
LANCET RESPIRATORY MEDICINE (2021)
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping
Xiuning Le et al.
JCO PRECISION ONCOLOGY (2021)
MET Exnn 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
Mark A. Socinski et al.
JCO PRECISION ONCOLOGY (2021)
Next-Generation Liquid Biopsies: Embracing Data Science in Oncology
Y. R. Im et al.
TRENDS IN CANCER (2021)
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models
John O. DaSilva et al.
CLINICAL CANCER RESEARCH (2020)
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2020)
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC
Gonzalo Recondo et al.
CLINICAL CANCER RESEARCH (2020)
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients
Giorgio Scagliotti et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
Florian Guisier et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
M. A. Pruis et al.
LUNG CANCER (2020)
TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors
Marco Gymnopoulos et al.
MOLECULAR ONCOLOGY (2020)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon et al.
NATURE MEDICINE (2020)
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2020)
Molecular profiling for precision cancer therapies
Eoghan R. Malone et al.
GENOME MEDICINE (2020)
Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
Elaine Kilgour et al.
CANCER CELL (2020)
Survival differences between smokers and nonsmokers with EGFR mutated non-small cell lung cancer.
David Macari et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms.
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
Jiyeon Yun et al.
CANCER DISCOVERY (2020)
Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients
Anne Champagnac et al.
JOURNAL OF THORACIC DISEASE (2020)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi-Long Wu et al.
LANCET RESPIRATORY MEDICINE (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
M. Schuler et al.
ANNALS OF ONCOLOGY (2020)
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test inMET-Addicted Cancer
Jooseok Kim et al.
CANCERS (2020)
MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
E. Felip et al.
ANNALS OF ONCOLOGY (2020)
MET-dependent solid tumours - molecular diagnosis and targeted therapy
Robin Guo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Targeting MET Dysregulation in Cancer
Gonzalo Recondo et al.
CANCER DISCOVERY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
When should we order a next generation sequencing test in a patient with cancer?
Ramon Colomer et al.
ECLINICALMEDICINE (2020)
Update 2020: Management of Non-Small Cell Lung Cancer
Mariam Alexander et al.
LUNG (2020)
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping
Joon Young Hur et al.
IN VIVO (2020)
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer
Gillianne Gy Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met plus non-small cell lung cancer by EGFR mutation status.
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
Kurtis D. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer
Jun Sakakibara-Konishi et al.
CLINICAL LUNG CANCER (2019)
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Robin Guo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
Jeffrey P. Gregg et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met
Mengya Tong et al.
CANCER SCIENCE (2019)
HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers
Fatemeh Moosavi et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2019)
How liquid biopsies can change clinical practice in oncology
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
Chang-yong Yang et al.
ACTA PHARMACOLOGICA SINICA (2019)
Should next-generation sequencing tests be performed on all cancer patients?
Andrew J. McKenzie et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non-Small Cell Lung Cancer
Richard A. Blidner et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report
Keisuke Baba et al.
THORACIC CANCER (2019)
Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Subba R. Digumarthy et al.
CANCERS (2019)
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
Henning Reis et al.
CLINICAL LUNG CANCER (2018)
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors
Meriem Sarah Mekki et al.
Oncotarget (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer
Magda Bahcall et al.
CLINICAL CANCER RESEARCH (2018)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
Jing Xu et al.
ONCOTARGET (2017)
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D. Engstrom et al.
CLINICAL CANCER RESEARCH (2017)
MET/HGF pathway activation as a paradigm of resistance to targeted therapies
Brian Ko et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC
Si-Yang Liu et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Rebecca S. Heist et al.
ONCOLOGIST (2016)
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
H. Yoshioka et al.
ANNALS OF ONCOLOGY (2015)
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor
Sai F. Yeung et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
Crizotinib Can Overcome Acquired Resistance to CH5424802
Toyokawa Gouji et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami et al.
CANCERS (2014)
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Determining Chemotherapy Tolerance in Older Patients With Cancer
Jerome Kim et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer
Giorgio V. Scagliotti et al.
CLINICAL LUNG CANCER (2012)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2009)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
Ryoichi Onozato et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
Katsuhiro Okuda et al.
CANCER SCIENCE (2008)
Quality control in molecular immunohistochemistry
Lawrence D. True
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort
Michele Beau-Faller et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
PC Ma et al.
CANCER RESEARCH (2005)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Share Paper
